GSK plc
GSK
$38.40
$0.441.16%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.47B | 10.40B | 10.43B | 9.95B | 9.34B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.47B | 10.40B | 10.43B | 9.95B | 9.34B |
| Cost of Revenue | 2.42B | 3.25B | 3.03B | 2.60B | 2.43B |
| Gross Profit | 7.04B | 7.15B | 7.40B | 7.34B | 6.91B |
| SG&A Expenses | 2.59B | 3.36B | 4.90B | 3.01B | 2.51B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -226.71M | 153.68M | -248.55M | -264.92M | -191.48M |
| Total Operating Expenses | 6.55B | 9.12B | 9.56B | 7.15B | 6.49B |
| Operating Income | 2.91B | 1.28B | 867.97M | 2.79B | 2.85B |
| Income Before Tax | 2.65B | 721.01M | 83.28M | 1.89B | 1.72B |
| Income Tax Expenses | 423.18M | 79.40M | -1.30M | 240.95M | 347.45M |
| Earnings from Continuing Operations | 2.23B | 641.61M | 84.59M | 1.64B | 1.37B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -186.40M | -111.42M | -160.06M | -165.26M | -44.38M |
| Net Income | 2.05B | 530.19M | -75.48M | 1.48B | 1.33B |
| EBIT | 2.91B | 1.28B | 867.97M | 2.79B | 2.85B |
| EBITDA | 3.95B | 1.96B | 2.11B | 3.60B | 3.55B |
| EPS Basic | 0.50 | 0.13 | -0.02 | 0.36 | 0.33 |
| Normalized Basic EPS | 0.38 | 0.14 | 0.07 | 0.36 | 0.40 |
| EPS Diluted | 0.50 | 0.13 | -0.02 | 0.36 | 0.32 |
| Normalized Diluted EPS | 0.38 | 0.14 | 0.07 | 0.35 | 0.40 |
| Average Basic Shares Outstanding | 4.09B | 4.08B | 4.08B | 4.08B | 4.07B |
| Average Diluted Shares Outstanding | 4.14B | 4.15B | 4.14B | 4.12B | 4.11B |
| Dividend Per Share | 0.20 | 0.20 | 0.20 | 0.19 | 0.19 |
| Payout Ratio | 37.68% | 147.83% | -1,055.17% | 55.58% | 54.30% |